Label: ADENOSINE- adenosine injection, solution
- NDC Code(s): 0409-1932-01, 0409-1932-02, 0409-1932-10, 0409-1932-12
- Packager: Hospira, Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
If you are a consumer or patient please visit this version.
- SPL UNCLASSIFIED SECTION
FOR INTRAVENOUS INFUSION ONLYRx only Close
Adenosine is an endogenous nucleoside occurring in all cells of the body. It is chemically 6-amino-9-beta-D-ribofuranosyl-9-H-purine and has the following structural formula:
Adenosine is a white, odorless crystalline powder. It is slightly soluble in water and practically insoluble in alcohol. Solubility increases by warming and lowering the pH of the solution.
Each adenosine injection vial contains a sterile, non-pyrogenic solution of adenosine 3 mg/mL and sodium chloride 9 mg/mL in water for injection, q.s. The pH of the solution is between 4.5 and 7.5.Close
- CLINICAL PHARMACOLOGY
Mechanism of Action
Adenosine is a potent vasodilator in most vascular beds, except in renal afferent arterioles and hepatic veins where it produces vasoconstriction. Adenosine is thought to exert its pharmacological effects through activation of purine receptors (cell-surface A1 and A2 adenosine receptors). Although the exact mechanism by which adenosine receptor activation relaxes vascular smooth muscle is not known, there is evidence to support both inhibition of the slow inward calcium current reducing calcium uptake, and activation of adenylate cyclase through A2 receptors in smooth muscle cells. Adenosine may also lessen vascular tone by modulating sympathetic neurotransmission. The intracellular uptake of adenosine is mediated by a specific transmembrane nucleoside transport system. Once inside the cell, adenosine is rapidly phosphorylated by adenosine kinase to adenosine monophosphate, or deaminated by adenosine deaminase to inosine. These intracellular metabolites of adenosine are not vasoactive.
Myocardial uptake of thallium-201 is directly proportional to coronary blood flow. Since adenosine injection significantly increases blood flow in normal coronary arteries with little or no increase in stenotic arteries, adenosine injection causes relatively less thallium-201 uptake in vascular territories supplied by stenotic coronary arteries i.e., a greater difference is seen after adenosine injection between areas served by normal and areas served by stenotic vessels than is seen prior to adenosine injection.
Adenosine produces a direct negative chronotropic, dromotropic and inotropic effect on the heart, presumably due to A1-receptor agonism, and produces peripheral vasodilation, presumably due to A2-receptor agonism. The net effect of adenosine injection in humans is typically a mild to moderate reduction in systolic, diastolic and mean arterial blood pressure associated with a reflex increase in heart rate. Rarely, significant hypotension and tachycardia have been observed.
Intravenously administered adenosine is rapidly cleared from the circulation via cellular uptake, primarily by erythrocytes and vascular endothelial cells. This process involves a specific transmembrane nucleoside carrier system that is reversible, nonconcentrative, and bidirectionally symmetrical. Intracellular adenosine is rapidly metabolized either via phosphorylation to adenosine monophosphate by adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol. Since adenosine kinase has a lower Km and Vmax than adenosine deaminase, deamination plays a significant role only when cytosolic adenosine saturates the phosphorylation pathway. Inosine formed by deamination of adenosine can leave the cell intact or can be degraded to hypoxanthine, xanthine, and ultimately uric acid. Adenosine monophosphate formed by phosphorylation of adenosine is incorporated into the high-energy phosphate pool. While extracellular adenosine is primarily cleared by cellular uptake with a half-life of less than 10 seconds in whole blood, excessive amounts may be deaminated by an ecto-form of adenosine deaminase. As adenosine injection requires no hepatic or renal function for its activation or inactivation, hepatic and renal failure would not be expected to alter its effectiveness or tolerability.
In two crossover comparative studies involving 319 subjects who could exercise (including 106 healthy volunteers and 213 patients with known or suspected coronary disease), adenosine injection and exercise thallium images were compared by blinded observers. The images were concordant for the presence of perfusion defects in 85.5% of cases by global analysis (patient by patient) and up to 93% of cases based on vascular territories. In these two studies, 193 patients also had recent coronary arteriography for comparison (healthy volunteers were not catheterized). The sensitivity (true positive adenosine injection divided by the number of patients with positive (abnormal) angiography) for detecting angiographically significant disease (≥50% reduction in the luminal diameter of at least one major vessel) was 64% for adenosine injection and 64% for exercise testing, while the specificity (true negative divided by the number of patients with negative angiograms) was 54% for adenosine injection and 65% for exercise testing. The 95% confidence limits for adenosine injection sensitivity were 56% to 78% and for specificity were 37% to 71%.
Intracoronary Doppler flow catheter studies have demonstrated that a dose of intravenous adenosine injection of 140 mcg/kg/min produces maximum coronary hyperemia (relative to intracoronary papaverine) in approximately 95% of cases within two to three minutes of the onset of the infusion. Coronary blood flow velocity returns to basal levels within one to two minutes of discontinuing the adenosine injection infusion.Close
- INDICATIONS AND USAGE
Intravenous adenosine injection should not be administered to individuals with:
- Second- or third-degree AV block (except in patients with a functioning artificial pacemaker).
- Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker).
- Known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma).
- Known hypersensitivity to adenosine.
Fatal Cardiac Arrest, Ventricular Arrhythmias, and Myocardial Infarction
Fatal and nonfatal cardiac arrest, sustained ventricular tachycardia (requiring resuscitation), and myocardial infarction have occurred following adenosine injection infusion. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example, unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reactions to adenosine injection. Appropriate resuscitative measures should be available.
Sinoatrial and Atrioventricular Nodal Block
Adenosine injection exerts a direct depressant effect on the SA and AV nodes and has the potential to cause first-, second- or third-degree AV block, or sinus bradycardia. Approximately 6.3% of patients develop AV block with adenosine injection including first-degree (2.9%), second-degree (2.6%), and third-degree (0.8%) heart block. Adenosine injection can cause sinus bradycardia. Adenosine injection should be used with caution in patients with pre-existing first-degree AV block or bundle branch block and should be avoided in patients with high-grade AV block or sinus node dysfunction (except in patients with a functioning artificial pacemaker). Adenosine injection should be discontinued in any patient who develops persistent or symptomatic high-grade AV block. Sinus pause has been rarely observed with adenosine infusions.
Adenosine injection is a potent peripheral vasodilator and can cause significant hypotension. Patients with an intact baroreceptor reflex mechanism are able to maintain blood pressure and tissue perfusion in response to adenosine injection by increasing heart rate and cardiac output. However, adenosine injection should be used with caution in patients with autonomic dysfunction, stenotic valvular heart disease, pericarditis or pericardial effusions, stenotic carotid artery disease with cerebrovascular insufficiency, or uncorrected hypovolemia, due to the risk of hypotensive complications in these patients. Adenosine injection should be discontinued in any patient who develops persistent or symptomatic hypotension.
Increases in systolic and diastolic pressure have been observed (as great as 140 mm Hg systolic in one case) concomitant with adenosine injection infusion; most increases resolved spontaneously within several minutes, but in some cases, hypertension lasted for several hours.
Adenosine injection is a respiratory stimulant (probably through activation of carotid body chemoreceptors) and intravenous administration in man has been shown to increase minute ventilation (Ve) and reduce arterial PCO2 causing respiratory alkalosis. Approximately 28% of patients experience breathlessness (dyspnea) or an urge to breathe deeply with adenosine injection. These respiratory complaints are transient and only rarely require intervention.
Adenosine administered by inhalation has been reported to cause bronchoconstriction in asthmatic patients, presumably due to mast cell degranulation and histamine release. These effects have not been observed in normal subjects. Adenosine injection has been administered to a limited number of patients with asthma and mild to moderate exacerbation of their symptoms has been reported. Respiratory compromise has occurred during adenosine infusion in patients with obstructive pulmonary disease. Adenosine injection should be used with caution in patients with obstructive lung disease not associated with bronchoconstriction (e.g., emphysema, bronchitis, etc.) and should be avoided in patients with bronchoconstriction or bronchospasm (e.g., asthma). Adenosine injection should be discontinued in any patient who develops severe respiratory difficulties.
Atrial fibrillation has been reported in patients (with and without a history of atrial fibrillation) undergoing myocardial perfusion imaging with adenosine infusion. In these cases, atrial fibrillation began 1.5 to 3 minutes after initiation of adenosine, lasted for 15 seconds to 6 hours, and spontaneously converted to normal sinus rhythm.Close
Intravenous adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, adenosine injection should be used with caution in the presence of these agents.
The vasoactive effects of adenosine injection are inhibited by adenosine receptor antagonists, such as methylxanthines (e.g., caffeine and theophylline). The safety and efficacy of adenosine injection in the presence of these agents has not been systematically evaluated.
The vasoactive effects of adenosine injection are potentiated by nucleoside transport inhibitors, such as dipyridamole. The safety and efficacy of adenosine injection in the presence of dipyridamole has not been systematically evaluated.
Whenever possible, drugs that might inhibit or augment the effects of adenosine should be withheld for at least five half-lives prior to the use of adenosine injection.
Carcinogenesis, mutagenesis, impairment of fertility
Studies in animals have not been performed to evaluate the carcinogenic potential of adenosine injection. Adenosine was negative for genotoxic potential in the Salmonella (Ames Test) and Mammalian Microsome Assay.
Adenosine, however, like other nucleosides at millimolar concentrations present for several doubling times of cells in culture, is known to produce a variety of chromosomal alterations.
Fertility studies in animals have not been conducted with adenosine.
Pregnancy Category C
Animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. Because it is not known whether adenosine injection can cause fetal harm when administered to pregnant women, adenosine injection should be used during pregnancy only if clearly needed.
The safety and effectiveness of adenosine injection in patients less than 18 years of age have not been established.
Clinical studies of adenosine injection did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently. Other reported experience has not revealed clinically relevant differences of the response of elderly in comparison to younger patients. Greater sensitivity of some older individuals, however, cannot be ruled out.Close
- ADVERSE REACTIONS
The following reactions with an incidence of at least 1% were reported with intravenous adenosine injection among 1421 patients enrolled in controlled and uncontrolled U.S. clinical trials. Despite the short half-life of adenosine, 10.6% of the side effects occurred not with the infusion of adenosine injection but several hours after the infusion terminated. Also, 8.4% of the side effects that began coincident with the infusion persisted for up to 24 hours after the infusion was complete. In many cases, it is not possible to know whether these late adverse events are the result of adenosine injection infusion.
Dyspnea or urge to breathe deeply
Throat, neck or jaw discomfort
Upper extremity discomfort
ST segment depression
First-degree AV block
Second-degree AV block
Adverse experiences of any severity reported in less than 1% of patients include:
Body as a Whole
Back discomfort; lower extremity discomfort; weakness
Nonfatal myocardial infarction; life-threatening ventricular arrhythmia; third-degree AV block; bradycardia; palpitation; sinus exit block; sinus pause; sweating; T-wave changes; hypertension (systolic blood pressure > 200 mm Hg)
Central Nervous System
Drowsiness; emotional instability; tremors
Vaginal pressure; urgency
Blurred vision; dry mouth; ear discomfort; metallic taste; nasal congestion; scotomas; tongue discomfort
Post Marketing Experience (see WARNINGS)
The following adverse events have been reported from marketing experience with adenosine injection. Because these events are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) frequency of the reporting, (3) strength of causal connection to the drug, or a combination of these factors.
Body as a Whole
Injection site reaction
Fatal and nonfatal cardiac arrest, myocardial infarction, ventricular arrhythmia
Central Nervous System
Seizure activity, including tonic clonic (grand mal) seizures, and loss of consciousness
Nausea and vomiting
Respiratory arrest, throat tightnessClose
The half-life of adenosine is less than 10 seconds and side effects of adenosine injection (when they occur) usually resolve quickly when the infusion is discontinued, although delayed or persistent effects have been observed. Methylxanthines, such as caffeine and theophylline, are competitive adenosine receptor antagonists and theophylline has been used to effectively terminate persistent side effects. In controlled U.S. clinical trials, theophylline (50 to 125 mg slow intravenous injection) was needed to abort adenosine injection side effects in less than 2% of patients.Close
- DOSAGE AND ADMINISTRATION
For intravenous infusion only.
Adenosine injection should be given as a continuous peripheral intravenous infusion.
The recommended intravenous dose for adults is 140 mcg/kg/min infused for six minutes (total dose of 0.84 mg/kg).
The required dose of thallium-201 should be injected at the midpoint of the adenosine injection infusion (i.e., after the first three minutes of adenosine injection). Thallium-201 is physically compatible with adenosine injection and may be injected directly into the adenosine injection infusion set.
The injection should be as close to the venous access as possible to prevent an inadvertent increase in the dose of adenosine injection (the contents of the IV tubing) being administered.
There are no data on the safety or efficacy of alternative adenosine injection infusion protocols.
The safety and efficacy of adenosine injection administered by the intracoronary route have not been established.
The following adenosine injection infusion nomogram may be used to determine the appropriate infusion rate corrected for total body weight:
This nomogram was derived from the following general formula:
0.14 (mg/kg/min) x total body weight (kg)
= Infusion rate (mL/min)
Adenosine injection concentration (3 mg/mL)
Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.Close
- HOW SUPPLIED
Adenosine Injection, USP is supplied as 20 mL and 30 mL vials of sterile, nonpyrogenic solution in normal saline.
Unit of Sale
Carton containing 25
60 mg/20 mL
20 mL single dose vial
Carton containing 25
90 mg/30 mL
30 mL single dose vial
Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature]
Do not refrigerate as crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature. The solution must be clear at the time of use.
Contains no preservative. Discard unused portion.
Gland Pharma Limited;
Hyderabad 500043, India
Lake Forest, IL 60045 USA
Made in India
- PRINCIPAL DISPLAY PANEL
RL-4466 (Outer Carton)
RL-4467 (Outer Carton)
CA-3459 (Inner Carton)
CA-3460 (Inner Carton)
- INGREDIENTS AND APPEARANCE
adenosine injection, solution
Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0409-1932 Route of Administration INTRAVENOUS DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength ADENOSINE (ADENOSINE) ADENOSINE 3 mg in 1 mL Inactive Ingredients Ingredient Name Strength SODIUM CHLORIDE WATER Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0409-1932-10 25 in 1 PACKAGE 1 NDC:0409-1932-01 20 mL in 1 VIAL 2 NDC:0409-1932-12 25 in 1 PACKAGE 2 NDC:0409-1932-02 30 mL in 1 VIAL Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA203883 03/24/2014 Labeler - Hospira, Inc. (141588017)